ClinicalTrials.gg

Program

artenimol

Also written as “Eurartesim™”, “Dihydroartemisinin tablets” and “Eurartesim”.

Its studies are mostly in Malaria, Falciparum · Malaria, Vivax · Lupus Erythematosus, Discoid · Lupus Erythematosus, Systemic, led by 4 companies.

Furthest: phase 2, since Apr 12, 20107 company-led studies, 1 open or runningNext primary completion: Sep 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
sigma-tau i.f.r.30 open or runningphase 1since Apr 12, 2010Apr 12, 2010none ahead
Kunming Pharmaceuticals21 open or runningphase 2since Jan 4, 2018Jan 4, 2018Sep 30, 2028phase 2 · NCT07557927
Alfasigma10 open or runningphase 2since Apr 8, 2014Apr 8, 2014none ahead
GlaxoSmithKline10 open or runningphase 1since Jul 3, 2014Jul 3, 2014none ahead

Also a collaborator on its studies: cpr-pharma-services-pty-ltd-australia.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 12, 2010First study: phase 1 study in Malaria, FalciparumNew to sigma-tau i.f.r.sigma-tau i.f.r. · NCT01103830 · 287 enrolled · France
  2. Oct 11, 20102 phase 1 studies in Malaria, Falciparumsigma-tau i.f.r. · NCT01222962, NCT01222949
  3. Apr 8, 2014Alfasigma's first study: phase 2 study in Malaria, VivaxNew to AlfasigmaAlfasigma · NCT02110784 · 27 enrolled · France, Germany, Israel and more
  4. Jul 3, 2014GlaxoSmithKline's first study: phase 1 study in Malaria, VivaxNew to GlaxoSmithKlineGlaxoSmithKline · NCT02184637 · 120 enrolled · United States
  5. Jan 4, 2018Kunming Pharmaceuticals's first study: phase 2 study in Lupus Erythematosus, SystemicNew to Kunming PharmaceuticalsKunming Pharmaceuticals · NCT03396393 · 120 enrolled
  6. Apr 22, 2026Phase 2 study in Lupus Erythematosus, DiscoidKunming Pharmaceuticals · NCT07557927 · 100 planned · China

Ahead

  1. Sep 30, 2028Primary completion: phase 2 study in Lupus Erythematosus, DiscoidKunming Pharmaceuticals · NCT07557927

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Ferriprotoporphyrin IX binding agent”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07557927Lupus Erythematosus, Discoid · China2Not yet recruitingKunming PharmaceuticalsSep 30, 2028100
NCT03396393Lupus Erythematosus, Systemic2UNKNOWNKunming PharmaceuticalsDec 2021120
NCT02184637Malaria, Vivax · United States1CompletedGlaxoSmithKlineApr 8, 2015120
NCT02110784Malaria, Vivax · France, Germany, Israel and more2TerminatedAlfasigmaNov 23, 201627
NCT01222962Malaria, Falciparum · Australia1Completedsigma-tau i.f.r.May 201037
NCT01222949Malaria, Falciparum · Australia1Completedsigma-tau i.f.r.Jul 201080
NCT01103830Malaria, Falciparum · France1Completedsigma-tau i.f.r.Aug 2010287

How it is read

Names in the registry

  • “Eurartesim™”, 3 entries
  • “Dihydroartemisinin tablets”, 2 entries
  • “Eurartesim”, 2 entries
  • “Eurartesim tablets”, 1 entry
  • “Dihydroartemisinin tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.